Last reviewed · How we verify
RGLS8429
RGLS8429 is a Small molecule drug developed by Regulus Therapeutics Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | RGLS8429 |
|---|---|
| Sponsor | Regulus Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of RGLS8429 in Healthy Volunteers (PHASE1)
- A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RGLS8429 CI brief — competitive landscape report
- RGLS8429 updates RSS · CI watch RSS
- Regulus Therapeutics Inc. portfolio CI
Frequently asked questions about RGLS8429
What is RGLS8429?
RGLS8429 is a Small molecule drug developed by Regulus Therapeutics Inc..
Who makes RGLS8429?
RGLS8429 is developed by Regulus Therapeutics Inc. (see full Regulus Therapeutics Inc. pipeline at /company/regulus-therapeutics-inc).
What development phase is RGLS8429 in?
RGLS8429 is in Phase 1.
Related
- Manufacturer: Regulus Therapeutics Inc. — full pipeline
- Compare: RGLS8429 vs similar drugs
- Pricing: RGLS8429 cost, discount & access